BioMarin Announces Second Quarter 2009 Financial Results
...8 exclude (1) stock compensation expense $34 million for 2009 and $25.3 million for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit transaction in 2008; (3) impairment charges of $5.9 million in 2009 and $4.1 m...La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial
Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial ...La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced updated interim antibody reduction data for the Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). The updated analyses reinforce ...BioMarin Announces First Quarter 2009 Financial Results
...arter of 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction classified as research and development expense in the first qua...lion for 2008; (2) upfront license fees of $8.8 million associated with the riquent transaction million in 2009 and $1.4 million associated with the Summit tra...BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
...e* $110 to $120 Costs Associated with riquent Deal** Up to $15 Interest Income ...d development expenses associated with the riquent deal ** Represents upfront costs associated with the riquent deal to be allocated between research and ...